ES2118940T3 - Peptidil-derivados utiles como inhibidores de la enzima conversora de la interleucina-1 beta. - Google Patents

Peptidil-derivados utiles como inhibidores de la enzima conversora de la interleucina-1 beta.

Info

Publication number
ES2118940T3
ES2118940T3 ES93905939T ES93905939T ES2118940T3 ES 2118940 T3 ES2118940 T3 ES 2118940T3 ES 93905939 T ES93905939 T ES 93905939T ES 93905939 T ES93905939 T ES 93905939T ES 2118940 T3 ES2118940 T3 ES 2118940T3
Authority
ES
Spain
Prior art keywords
formula
interleukin
converting enzyme
beta
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93905939T
Other languages
English (en)
Inventor
Kevin T Chapman
Malcolm Maccoss
Adnan Mjalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2118940T3 publication Critical patent/ES2118940T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

NUEVOS DERIVADOS DE PEPTIDILO DE LA FORMULA (I) QUE SE HA DESCUBIERTO SON POTENTES INHIBIDORES DE LA ENZIMA CONVERSORA DE LA INTERLEUQUINA-1(BETA) (ICE). LOS COMPUESTOS DE LA FORMULA (I) SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS O DE BASE INMUNE DEL PULMON Y DE LAS VIAS RESPIRATORIAS; DEL SISTEMA NERVIOSO CENTRAL Y DE LAS MEMBRANAS QUE LO RODEAN; LOS OJOS Y LOS OIDOS; LAS ARTICULACIONES, LOS HUESOS Y LOS TEJIDOS CONECTIVOS; DEL SISTEMA CARDIOVASCULAR INCLUIDO EL PERICARDIO; DEL SISTEMA GASTROINTESTINAL Y DEL UROGENITAL; DE LA PIEL Y DE LAS MEMBRANAS MUCOSAS. LOS COMPUESTO DE LA FORMULA (I) TAMBIEN SON UTILES PARA EL TRATAMIENTO DE COMPLICACIONES DE INFECCIONES (EJ. CONMOCION GRAM NEGATIVA) Y DE TUMORES EN QUE LA IL-1(BETA) FUNCIONA COMO HORMONA DE CRECIMIENTO AUTOCRINA O COMO MEDIADORA DE LA CAQUEXIA.
ES93905939T 1992-02-21 1993-02-12 Peptidil-derivados utiles como inhibidores de la enzima conversora de la interleucina-1 beta. Expired - Lifetime ES2118940T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83959092A 1992-02-21 1992-02-21

Publications (1)

Publication Number Publication Date
ES2118940T3 true ES2118940T3 (es) 1998-10-01

Family

ID=25280154

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93905939T Expired - Lifetime ES2118940T3 (es) 1992-02-21 1993-02-12 Peptidil-derivados utiles como inhibidores de la enzima conversora de la interleucina-1 beta.

Country Status (9)

Country Link
US (1) US5430128A (es)
EP (1) EP0627926B1 (es)
JP (1) JP3386125B2 (es)
AT (1) ATE169224T1 (es)
AU (1) AU3666893A (es)
CA (1) CA2129976C (es)
DE (1) DE69320176T2 (es)
ES (1) ES2118940T3 (es)
WO (1) WO1993016710A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
EP0672151A1 (en) * 1992-06-12 1995-09-20 Massachusetts Institute Of Technology Inhibitors of ced-3 and related proteins
EP0618223A3 (en) * 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.
CA2122227A1 (en) * 1993-04-29 1994-10-30 Roland E. Dolle Peptide analogs as irreversible interleukin-1.beta. protease inhibitors
US5985838A (en) * 1993-04-29 1999-11-16 Vertex Pharmaceuticals, Inc. Peptide analogs as irreversible interleukin-1β protease inhibitors
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) * 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5565430A (en) * 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
GB2292149A (en) * 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
WO1996030395A2 (en) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5798442A (en) * 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
JP2002515730A (ja) * 1995-10-16 2002-05-28 カイロン コーポレイション 遺伝子発現を変調する因子のスクリーニング方法
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6288037B1 (en) 1996-01-29 2001-09-11 Basf Aktiengesellschaft Substrates and inhibitors for cysteine protease ICH-1
GB9621985D0 (en) 1996-10-22 1996-12-18 Peptide Therapeutics Ltd A solid-phase technology for the preparation of libraries of bi-directally functionalised drug-like molecules
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
ATE296812T1 (de) 1998-03-09 2005-06-15 Vertex Pharma 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms
DE69925268T2 (de) * 1998-03-16 2006-03-23 Cytovia, Inc., San Diego Dipeptid-Caspase-Inhibitoren und deren Verwendung
JP4594520B2 (ja) 1998-03-19 2010-12-08 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼのインヒビター
CA2336201A1 (en) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
JP2002539183A (ja) * 1999-03-16 2002-11-19 サイトビア インコーポレイテッド 置換２−アミノベンズアミドカスパーゼインヒビターおよびその使用
CA2369619A1 (en) 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
IL148426A0 (en) 1999-08-27 2002-09-12 Cytovia Inc α-HYDROXY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
AU2001259758A1 (en) 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
JP2004521080A (ja) 2000-09-08 2004-07-15 メルク フロスト カナダ アンド カンパニー カスパーゼ−３阻害薬としてのγ−ケト酸ジペプチド類
EP1485107A1 (en) * 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
US7615212B2 (en) 2004-02-26 2009-11-10 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP2008500374A (ja) 2004-05-27 2008-01-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド 自己炎症性疾患の処置のためのｉｃｅインヒビター
EP2635906A4 (en) 2010-11-05 2014-04-02 Univ Brandeis Ice inhibiting compounds and uses thereof
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055451A (en) * 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
AU7775991A (en) * 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
GB9123326D0 (en) * 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
EP0618223A3 (en) * 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.

Also Published As

Publication number Publication date
JPH07504194A (ja) 1995-05-11
DE69320176T2 (de) 1999-04-08
EP0627926A1 (en) 1994-12-14
WO1993016710A1 (en) 1993-09-02
CA2129976A1 (en) 1993-09-02
EP0627926A4 (en) 1997-01-29
DE69320176D1 (de) 1998-09-10
EP0627926B1 (en) 1998-08-05
ATE169224T1 (de) 1998-08-15
CA2129976C (en) 2002-09-17
US5430128A (en) 1995-07-04
AU3666893A (en) 1993-09-13
JP3386125B2 (ja) 2003-03-17

Similar Documents

Publication Publication Date Title
ES2118940T3 (es) Peptidil-derivados utiles como inhibidores de la enzima conversora de la interleucina-1 beta.
CA2071674A1 (en) Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
ES2175087T3 (es) Compuestos triciclicos utiles en el tratamiento de trastornos de proliferacion celular.
AU4783885A (en) Tetralin derivatives, their preparation and their use
BR9508057A (pt) Composto
MX9702658A (es) Derivados novedosos de acido carboxilico, su preparacion y uso.
AU1331588A (en) Method for treatment of alcohol abuse
GR3032220T3 (en) Use of 2-(N-(2-aminoethyl)amino)acetic acid derivatives for the treatment of diseases which are mediated by non-enzymatical glycosylation
EP0261336A3 (en) Process for the preparation of pure enantiomers of r-(+)-alpha-lipoic acid and s-(-)-alpha-lipoic acid (thioctic acid), and nonene or mesyl derivatives as intermediates therefor
PL332640A1 (en) Sulphonamide-group substituted derivatives of aspartic acid as inhibitors of an interleukin-1beta transforming enzyme
AU2165088A (en) Bacterial treatment to preserve hay quality by addition of microorganisms of the genus bacillus
CA2320388A1 (en) Novel dihydroxyhexanoic acid derivatives
BR9509970A (pt) Composto
AU5786690A (en) Process for purifying tryptophan
EP0230053A3 (en) 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids
AU2634597A (en) Compounds with growth hormone releasing properties
HUT50338A (en) Process for producing new 4-thiazolidinecarboxylic acid derivative and pharmaceutical compositions comprising same as active ingredient
ES2029846T3 (es) Procedimiento de preparacion de esteres de aminoacidos de alcoholes cicloalifaticos.
BG98761A (en) Substituted pyrroles
CA2188176A1 (fr) (oxo-1 alkyl) amino-2, deoxy-2 glucopyranoside de dihydroxy - 2,3 propyl, leur procede de preparation et leurs utilisations
RU95105169A (ru) Способ лечения инфекционных болезней, вызываемых h.pyl opi
AU5915794A (en) Pharmaceutical for the treatment of skin disorders
ATE86974T1 (de) (2-cyan-2-oximinoacetyl)-aminosaeure-derivate.
AU7016491A (en) Use of benzylphosphonic acid derivatives for the treatment of diseases caused by viruses
IL93197A0 (en) Derivatives of 3-pyroglutamyl-thia-zolidine-4-carboxylic acid

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 627926

Country of ref document: ES